Procyrion Australia Pty Ltd
Procyrion is developing the Aortix™ percutaneous mechanical circulatory support device aimed at treating heart failure patients who are too sick for medication alone. The device is designed to reduce cardiac workload, increase renal perfusion, and can be deployed percutaneously in less than 10 minutes. It aims to address the large and growing unmet clinical need of cardiorenal syndrome, which affects over 6 million adults in the U.S. and results in significant hospitalizations, deaths, and economic costs. Procyrion's technology has received recognition and awards, and is currently under clinical evaluation for indications including acute decompensated heart failure and renal support.
Industries
Nr. of Employees
small (1-50)
Procyrion Australia Pty Ltd
Patents
Method and apparatus for long-term assisting a left ventricle to pump blood
US-11745005-B2
View Details
Method and apparatus for long-term assisting a left ventricle to pump blood
US-11745005-B2
View DetailsProducts
Investigational percutaneous intra-aortic circulatory support pump
An investigational catheter-delivered axial-flow pump designed to be implanted in the descending aorta to reduce cardiac afterload and increase downstream aortic flow with the goal of improving cardiac efficiency and renal perfusion. Intended clinical uses under evaluation include acute decompensated heart failure with diuretic resistance and perioperative renal protection.
Investigational percutaneous intra-aortic circulatory support pump
An investigational catheter-delivered axial-flow pump designed to be implanted in the descending aorta to reduce cardiac afterload and increase downstream aortic flow with the goal of improving cardiac efficiency and renal perfusion. Intended clinical uses under evaluation include acute decompensated heart failure with diuretic resistance and perioperative renal protection.
Services
Design and conduct of pilot studies and pivotal IDE trials for investigational transcatheter circulatory support devices, including multi-site enrollment and investigation of renal and hemodynamic endpoints.
Engineering, preclinical testing, and iterative optimization of a catheter-delivered circulatory pump using CFD, bench testing, and large-animal studies to support human evaluation.
Establishment and maintenance of QMS aligned with ISO 13485 and relevant US regulations, and management of regulatory interactions and coding/reimbursement activities.
Design and conduct of pilot studies and pivotal IDE trials for investigational transcatheter circulatory support devices, including multi-site enrollment and investigation of renal and hemodynamic endpoints.
Engineering, preclinical testing, and iterative optimization of a catheter-delivered circulatory pump using CFD, bench testing, and large-animal studies to support human evaluation.
Establishment and maintenance of QMS aligned with ISO 13485 and relevant US regulations, and management of regulatory interactions and coding/reimbursement activities.
Expertise Areas
- Clinical trial management for investigational medical devices
- Percutaneous mechanical circulatory support (pMCS) device development
- Transcatheter implantation and procedural workflows
- Cardiorenal syndrome and acute decompensated heart failure therapeutics
Key Technologies
- Percutaneous catheter-delivered axial-flow pumps
- Intra-aortic continuous-flow pump mechanics
- Catheter-based trans-femoral delivery systems
- Micro-motor driven continuous-flow mechanisms
News & Updates
Lucas Buchanan, an industry veteran with expertise in commercialization, operations, business development, and finance, has been appointed to Procyrion's Board of Directors as it continues its pivotal IDE trial and prepares for US commercialization of its Aortix technology.
Procyrion was recognized as a Fierce15 Medtech company in 2023, highlighting its innovative Aortix™ technology and its potential to change treatment for acute decompensated heart failure and cardiorenal syndrome.
Procyrion announced the completion of a $57.7 million Series E funding round, including the conversion of $10 million of interim financing, to support its clinical trials and development.
The company announced the enrollment of the first patients in its IDE pivotal trial for the Aortix™ device, aimed at treating acute decompensated heart failure with persistent congestion.
Procyrion successfully secured new inpatient hospital ICD-10-PCS procedure codes applicable to its Aortix™ technology.
A pilot study showed that the Aortix™ device led to rapid decongestion and improved renal function in patients with heart failure and worsening renal function.
Lucas Buchanan, an industry veteran with expertise in commercialization, operations, business development, and finance, has been appointed to Procyrion's Board of Directors as it continues its pivotal IDE trial and prepares for US commercialization of its Aortix technology.
Procyrion was recognized as a Fierce15 Medtech company in 2023, highlighting its innovative Aortix™ technology and its potential to change treatment for acute decompensated heart failure and cardiorenal syndrome.
Procyrion announced the completion of a $57.7 million Series E funding round, including the conversion of $10 million of interim financing, to support its clinical trials and development.
The company announced the enrollment of the first patients in its IDE pivotal trial for the Aortix™ device, aimed at treating acute decompensated heart failure with persistent congestion.
Procyrion successfully secured new inpatient hospital ICD-10-PCS procedure codes applicable to its Aortix™ technology.
A pilot study showed that the Aortix™ device led to rapid decongestion and improved renal function in patients with heart failure and worsening renal function.